Phase 2 Study of Adebrelimab Combined with Nab-paclitaxel and Carboplatin Before Surgery for Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

What this Trial Is About

Researchers are studying the use of adebrelimab combined with albumin-bound paclitaxel and carboplatin as a pre-surgery treatment for patients with borderline resectable locally advanced esophageal squamous cell carcinoma ESCC. The goal is to improve the rate of complete tumor removal R0 resection, reduce the chance of cancer coming back, and improve overall survival, while avoiding side effects linked to radiotherapy. Participants receive the combination treatment in cycles lasting three weeks each. After two cycles, doctors evaluate the cancers response if it becomes operable, surgery is performed if not, patients may receive chemoradiotherapy or other advanced treatments. Those with partial improvement may get a third cycle before reassessment. Depending on surgical outcomes, further treatments like adjuvant therapy or chemoradiotherapy may be recommended. Throughout the study, participants undergo regular evaluations including imaging and clinical assessments to monitor tumor response and safety. Researchers measure outcomes such as the rate of successful tumor removal, overall survival up to five years, progression-free survival, complete pathological response, complications around surgery, and tumor regression grade. The entire participation may span several years with follow-up to assess long-term outcomes.

Adebrelimab Combined With Neoadjuvant Chemotherapy in Borderline Resectable Locally Advanced Esophageal Squamous Cell Carcinoma